Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Pierce

Showing results (511-520 of 548) with videos related to

Pageof 55
Sort By:
Thrombosis and Haemostasis|December 23, 2016
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia BK John Pasi, Kathelijn Fischer, Margaret Ragni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2024
FDA Approval Summary: Capecitabine Labeling Update under Project RenewalSundeep Agrawal, Clara Lee, William F Pierce, et al.
Lancet (London, England)|March 30, 2005
Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trialF T Cutts, S M A Zaman, G Enwere, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial CarcinomaMichael H Brave, William F Maguire, Chana Weinstock, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 4, 2020
WFH Guidelines for the Management of Hemophilia, 3rd editionAlok Srivastava, Elena Santagostino, Alison Dougall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2018
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Erik Bloomquist, Shenghui Tang, et al.
Journal of Thrombosis and Haemostasis : JTH|September 9, 2014
Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levelsA D Shapiro, M V Ragni, R Kulkarni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast CancerPreeti Narayan, Christy L Osgood, Harpreet Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2018
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast CancerHarpreet Singh, Amanda J Walker, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast CancerMirat Shah, Suparna Wedam, Joyce Cheng, et al.
Pageof 55

Showing results (511-520 of 548) with videos related to

Sort By:
Pageof 55
Thrombosis and Haemostasis|December 23, 2016
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia BK John Pasi, Kathelijn Fischer, Margaret Ragni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2024
FDA Approval Summary: Capecitabine Labeling Update under Project RenewalSundeep Agrawal, Clara Lee, William F Pierce, et al.
Lancet (London, England)|March 30, 2005
Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trialF T Cutts, S M A Zaman, G Enwere, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial CarcinomaMichael H Brave, William F Maguire, Chana Weinstock, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 4, 2020
WFH Guidelines for the Management of Hemophilia, 3rd editionAlok Srivastava, Elena Santagostino, Alison Dougall, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2018
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Erik Bloomquist, Shenghui Tang, et al.
Journal of Thrombosis and Haemostasis : JTH|September 9, 2014
Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levelsA D Shapiro, M V Ragni, R Kulkarni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast CancerPreeti Narayan, Christy L Osgood, Harpreet Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2018
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast CancerHarpreet Singh, Amanda J Walker, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast CancerMirat Shah, Suparna Wedam, Joyce Cheng, et al.
Pageof 55